Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain
Abstract
This study addresses the need to phase out opioids as the major analgesic drugs for moderate to severe chronic pain. We establish that a highly selective and potent inhibitor of the α9α10 nicotinic acetylcholine receptor (nAChR) subtype prevents the expression of chemotherapy-induced neuropathic pain. Thus, selective antagonists of the α9α10 nAChR are potential leads for nonopioid analgesic drug development. The effects of inhibitors of the α9α10 receptor, together with genetic studies, suggest a key role for the α9α10 nAChR subtype in an intercellular signaling network that can be activated by diverse insults (e.g., chemotherapy, nerve injury, and diabetes).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 21, 2017
- Source ID
- 10.1073/pnas.1621433114
Entities
People
- Baldomera M. Olivera
- Carla Ghelardini
- Douglas E. Vetter
- Haylie K. Romero
- J. Michael Mcintosh
- Joanna Gajewiak
- Jose L. Mercado
- Keith S. Elmslie
- Lorenzo Di Cesare Mannelli
- Renuka Ramachandra
- Sean B. Christensen
- Shawn P. Iadonato
Organizations
- A.T. Still University
- National Institute of General Medical Sciences
- National Institutes of Health
- United States Department of Defense
- University of Florence
- University of Mississippi
- University of Utah